Stock Events

Stock Events

Entera Bio 

$3.29
45
+$0.07+2.17% 16:22 Today

Statistics

Day High
3.34
Day Low
3.18
52W High
4.2
52W Low
0.91
Volume
150,514
Avg. Volume
2,598,488
Mkt Cap
569.64M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.14
-0.07
-0.01
0.06
Expected EPS
-0.08
Actual EPS
N/A

Financials

-27,235.71%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
42,000Revenue
-11.44MNet Income

Analyst Ratings

9.00Average Price Target
The highest estimate is 9.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ENTX. It's not an investment recommendation.
Apple
10
AAPL
Microsoft
9
MSFT
NVIDIA
9
NVDA
AT&T
8
T

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotech company that develops novel therapies, including for bone diseases, which competes with Entera Bio's focus on osteoporosis treatments.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie has a strong portfolio in biopharmaceuticals, including treatments for conditions that Entera Bio targets, making them direct competitors in the biotech space.
Biomarin Pharmaceutical
BMRN
Mkt Cap13.04B
BioMarin Pharmaceutical focuses on enzyme replacement therapies, some of which may overlap with Entera Bio's therapeutic areas, including bone diseases.
Pfizer
PFE
Mkt Cap152.69B
Pfizer has a broad range of healthcare products, including treatments for endocrine disorders, directly competing with Entera Bio's development pipeline.
Novo Nordisk
NVO
Mkt Cap201.05B
Novo Nordisk specializes in diabetes care and biopharmaceuticals, including hormone replacement therapies that could compete with Entera Bio's products.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals is involved in developing and commercializing products for bone disorders among other areas, positioning them as competitors to Entera Bio.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals engages in creating novel therapies for a range of diseases, including those in Entera Bio's interest areas, making them a competitor.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences' focus on innovative therapeutics in areas like bone health can put them in direct competition with Entera Bio's product line.

About

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.
Show more...
CEO
Miranda J. Toledano
Employees
22
Country
Israel
ISIN
IL0011429839
WKN
000A2JQXP

Listings

STU
DE
5DT.STU
XNAS
US
ENTX
BOATS
BOATS
ENTX.BOATS
F
DE
5DT.F

0 Comments

Share your thoughts

FAQ

What is Entera Bio stock price today?▼
The current price of ENTX is $3.29 USD — it has increased by +2.17% in the past 24 hours. Watch Entera Bio stock price performance more closely on the chart.
What is Entera Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Entera Bio stocks are traded under the ticker ENTX.
Is Entera Bio stock price growing?▼
ENTX stock has risen by +13.15% compared to the previous week, the month change is a +66.84% rise, over the last year Entera Bio has showed a +67.69% increase.
What is Entera Bio market cap?▼
Today Entera Bio has the market capitalization of 569.64M
When is the next Entera Bio earnings date?▼
Entera Bio is going to release the next earnings report on November 05, 2026.
What were Entera Bio earnings last quarter?▼
ENTX earnings for the last quarter are -0.14 USD per share, whereas the estimation was -0.08 USD resulting in a -75% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Entera Bio revenue for the last year?▼
Entera Bio revenue for the last year amounts to 42,000 USD.
What is Entera Bio net income for the last year?▼
ENTX net income for the last year is -11.44M USD.
How many employees does Entera Bio have?▼
As of August 21, 2026, the company has 22 employees.
In which sector is Entera Bio located?▼
Entera Bio operates in the Health & Wellness sector.
When did Entera Bio complete a stock split?▼
Entera Bio has not had any recent stock splits.
Where is Entera Bio headquartered?▼
Entera Bio is headquartered in JERUSALEM, Israel.